<DOC>
	<DOCNO>NCT02243631</DOCNO>
	<brief_summary>This study investigate hypothesis probenecid , medication currently use gout , reduces level ATP joint fluid patient calcium pyrophosphate deposition disease ( CPPD ) , another common type crystal-related arthritis . There good evidence CPPD result excess ATP joint . The investigator measure level ATP joint fluid 5 day treatment probenecid . This study serve rationalize large study probenecid CPPD .</brief_summary>
	<brief_title>Effect Probenecid Synovial Fluid ATP Levels CPPD</brief_title>
	<detailed_description>Objective : The objective study determine whether pharmacologic dos drug probenecid significantly decrease ATP inorganic pyrophosphate ( PPi ) level synovial fluid patient calcium pyrophosphate deposition disease ( CPPD ) . The investigator considerable evidence synovial fluid ATP level high patient disease high level lead calcium pyrophosphate ( CPP ) crystal formation produce acute chronic arthritis . The investigator identify transmembrane protein know ANK chief regulator ATP level around cartilage . Probenecid block function ANK vitro . The purpose study determine probenecid use normal dos sufficient block ANK function vivo whether result reduce ATP PPi level synovial fluid . Research design : This randomize un-controlled trial probenecid vs. drug patient joint effusion know CPPD . Methodology : Power analysis base 80 % chance show 20 % difference ATP level treatment group result sample size 20 patient group . Patients know CPPD joint effusion arthrocentesis remove 2 ml synovial fluid joint . Fluid send investigator ' research laboratory ATP PPi level measure . Patients randomize treatment 2 grams/day probenecid therapy . After 5 day , remainder joint fluid remove tested ATP PPi level . The investigator compare difference ATP PPi level probenecid treat untreated group .</detailed_description>
	<mesh_term>Chondrocalcinosis</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<criteria>Inclusion criterion : Age &gt; 21 year , CPPD diagnose Ryan /McCarty criterion Joint effusion shoulder knee Exclusion criterion : Inability sign inform consent Age &lt; 21 year History renal stone Significant renal dysfunction ( CKD &gt; stage 2 ) Blood dyscrasia Current use drug interact probenecid Concurrent gout Active infection , include bacteremia overlie cellulitis Recent joint trauma Intraarticular corticosteroid affect joint within three month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ATP</keyword>
	<keyword>Probenecid</keyword>
	<keyword>Chondrocalcinosis</keyword>
</DOC>